Eli Lilly's Retatrutide Shows Over 28% Weight Loss, Orforglipron 12.4% in Trials
LLY sits 85% above its 52-week low of $623.78.
Summary
Eli Lilly reported exceptionally strong clinical trial results for two investigational obesity drugs. Retatrutide achieved over 28% weight loss at 18 months, alongside improvements in blood sugar, sleep apnea, and knee pain. Separately, oral GLP-1 orforglipron demonstrated 12.4% average weight loss over 72 weeks. These results significantly bolster Eli Lilly's leading position in the rapidly growing weight-loss market, with retatrutide's efficacy potentially setting a new benchmark for the industry.
At the time of this announcement, LLY was trading at $1,155.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.